Literature DB >> 34549903

Early-onset, fatal interstitial lung disease in STAT3 gain-of-function patients.

Florian Gothe1, Jonathan Gehrig2, Christina K Rapp1, Katrin Knoflach1, Simone Reu-Hofer3, Florian Länger4,5, Dirk Schramm6, Julia Ley-Zaporozhan7, Stephan Ehl2,8, Nicolaus Schwerk5,9, Laura Faletti2,8, Matthias Griese1,10.   

Abstract

Gain-of-function variants in STAT3 are known to cause severe, multifaceted autoimmunity. Here we report three individuals with de-novo STAT3 GOF alleles and early-onset, severe interstitial lung disease manifesting during the first 3 years of life. Imaging and histology revealed different forms of interstitial pneumonia alongside fibrotic and cystic tissue destruction. Definitive diagnosis was established by postmortem whole exome sequencing and functional validation of two new STAT3 variants. Such lung-predominant forms of STAT3 GOF disease expand the phenotypic spectrum of diseases associated with activating STAT3 variants and add to our understanding of this life-threatening inborn error of immunity.
© 2021 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC.

Entities:  

Keywords:  STAT3; autoimmunity; inborn error of immunity; interstitial lung disease

Mesh:

Substances:

Year:  2021        PMID: 34549903     DOI: 10.1002/ppul.25684

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  2 in total

1.  A Novel STAT3 Gain-of-Function Mutation in Fatal Infancy-Onset Interstitial Lung Disease.

Authors:  Mengyue Deng; Yue Li; Yulu Li; Xiaolan Mao; Han Ke; Weiling Liang; Xiaoguang Lei; Yu-Lung Lau; Huawei Mao
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

2.  Pirfenidone inhibits cell fibrosis in connective tissue disease-associated interstitial lung disease by targeting the TNF-α/STAT3/KL6 pathway.

Authors:  Yanhua Zuo; Jing Liu; Huaheng Xu; Yanxia Li; Ran Tao; Zongfang Zhang
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.